← Discussions
Product researchEditorial starter

GH Boost: what the research says about CJC-1295 and Ipamorelin

GH Boost combines CJC-1295 and Ipamorelin. The research section below covers each one.

GH Boost from USA Standard Research: dissolving strips, CJC-1295 250 mcg and ipamorelin 250 mcg per strip, 30 strips. Sold for research use only.

Editorial discussion starter: which finding would you like explained, and what does the research leave open? Share public sources. Please leave out personal medical details and dosing.

The research

CJC-1295

A synthetic GHRH analogue; its long-acting DAC form raised growth hormone and IGF-I for days in small studies of healthy adults.

Small human studies of the DAC form

What it is studied for

CJC-1295 with DAC was developed as a long-acting way to raise the body's own growth hormone. Two randomized, placebo-controlled trials in healthy adults measured growth hormone, IGF-I and safety after injections, and another study tracked overnight growth-hormone pulses in healthy men aged 20 to 40.

What the evidence says

Single injections raised growth hormone 2- to 10-fold for 6 days or more and IGF-I for 9 to 11 days, with natural pulses preserved. The studies did not measure lean or fat mass. Reported effects included injection reactions, flushing and faster heart rate; a 2006 trial in HIV patients stopped after a death the attending doctor thought most likely due to silent heart disease.

Full CJC-1295 profile and sources

Ipamorelin

A synthetic peptide that acts on the ghrelin receptor to trigger short growth hormone pulses; a surgery trial found no benefit over placebo.

Small human trials; animal research

What it is studied for

Ipamorelin was developed as a selective growth hormone releaser. In healthy men, intravenous infusions were used to model its blood levels and growth hormone response. A phase 2 trial in 114 bowel-surgery patients tested whether it shortened the time until they could tolerate a solid meal.

What the evidence says

In healthy men, growth hormone peaked about 40 minutes after an infusion and fell to low levels within hours. In the surgery trial it did not beat placebo. The authors called it well tolerated, but FDA noted two deaths in the ipamorelin group, though it is unclear whether they were drug-related, and more low potassium and high blood sugar.

Full Ipamorelin profile and sources

Sold by USA Standard Research, the team behind PeptidesGenie, for research use only. Not for human or veterinary use.

Research cited

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
Research guide (PDF)

0 replies

Have a useful source or a question to add? Start the conversation.

Join the conversation

Sign in to share a source or add a reply.